Negroiu Cristina Elena, Riza Anca-Lelia, Streață Ioana, Tudorașcu Iulia, Beznă Cristina Maria, Ungureanu Adrian Ionuț, Dănoiu Suzana
Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200642 Craiova, Romania.
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Curr Issues Mol Biol. 2024 Aug 3;46(8):8512-8525. doi: 10.3390/cimb46080501.
Fibroblast growth factor 21 (FGF21) is a hormone involved in regulating the metabolism, energy balance, and glucose homeostasis, with new studies demonstrating its beneficial effects on the heart. This study investigated the relationship between FGF21 levels and clinical, biochemical, and echocardiographic parameters in patients with acute coronary syndromes (ACSs). This study included 80 patients diagnosed with ACS between May and July 2023, categorized into four groups based on body mass index (BMI): Group 1 (BMI 18.5-24.9 kg/m), Group 2 (BMI 25-29.9 kg/m), Group 3 (BMI 30-34.9 kg/m), and Group 4 (BMI ≥ 35 kg/m). Serum FGF21 levels were measured by ELISA (Abclonal Catalog NO.: RK00084). Serum FGF21 levels were quantifiable in 55 samples (mean ± SD: 342.42 ± 430.17 pg/mL). Group-specific mean FGF21 levels were 238.98 pg/mL ± SD in Group 1 (n = 14), 296.78 pg/mL ± SD in Group 2 (n = 13), 373.77 pg/mL ± SD in Group 3 (n = 12), and 449.94 pg/mL ± SD in Group 4 (n = 16), with no statistically significant differences between groups ( = 0.47). Based on ACS diagnoses, mean FGF21 levels were 245.72 pg/mL for STEMI (n = 21), 257.89 pg/mL for NSTEMI (n = 9), and 456.28 pg/mL for unstable angina (n = 25), with no significant differences observed between these diagnostic categories. Significant correlations were identified between FGF21 levels and BMI, diastolic blood pressure, and serum chloride. Regression analyses revealed correlations with uric acid, chloride, and creatinine kinase MB. This study highlights the complex interplay between FGF21, BMI, and acute coronary syndromes. While no significant differences were found in FGF21 levels between the different BMI and ACS diagnostic groups, correlations with clinical and biochemical parameters suggest a multifaceted role of FGF21 in cardiovascular health. Further research with a larger sample size is warranted to elucidate these relationships.
成纤维细胞生长因子21（FGF21）是一种参与调节新陈代谢、能量平衡和葡萄糖稳态的激素，新研究表明其对心脏有有益作用。本研究调查了急性冠状动脉综合征（ACS）患者中FGF21水平与临床、生化及超声心动图参数之间的关系。本研究纳入了2023年5月至7月间诊断为ACS的80例患者，根据体重指数（BMI）分为四组：第1组（BMI 18.5 - 24.9 kg/m）、第2组（BMI 25 - 29.9 kg/m）、第3组（BMI 30 - 34.9 kg/m）和第4组（BMI≥35 kg/m）。采用酶联免疫吸附测定法（ELISA，Abclonal Catalog NO.: RK00084）检测血清FGF21水平。55份样本中的血清FGF21水平可定量（均值±标准差：342.42±430.17 pg/mL）。第1组（n = 14）的组特异性平均FGF21水平为238.98 pg/mL±标准差，第2组（n = 13）为296.78 pg/mL±标准差，第3组（n = 12）为373.77 pg/mL±标准差，第4组（n = 16）为449.94 pg/mL±标准差，各组之间无统计学显著差异（P = 0.47）。基于ACS诊断，ST段抬高型心肌梗死（STEMI，n = 21）的平均FGF21水平为245.72 pg/mL，非ST段抬高型心肌梗死（NSTEMI，n = 9）为257.89 pg/mL，不稳定型心绞痛（n = 25）为456.28 pg/mL，这些诊断类别之间未观察到显著差异。FGF21水平与BMI、舒张压和血清氯化物之间存在显著相关性。回归分析显示与尿酸、氯化物和肌酸激酶MB存在相关性。本研究强调了FGF21、BMI和急性冠状动脉综合征之间复杂的相互作用。虽然不同BMI和ACS诊断组之间的FGF21水平未发现显著差异，但与临床和生化参数的相关性表明FGF21在心血管健康中具有多方面作用。有必要进行更大样本量的进一步研究以阐明这些关系。
